Abbott's Humira gets FDA approval for active ankylosing spondylitis

By Elaine Rigoli

Tampa, Fla., July 31 - The Food and Drug Administration approved Abbott's Humira (adalimumab) for reducing signs and symptoms in patients with autoimmune disease active ankylosing spondylitis.

The company said active ankylosing spondylitis is the third of six autoimmune diseases targeted for Humira therapy that has received FDA approval.

Humira is approved by the FDA to treat rheumatoid arthritis and psoriatic arthritis.

The company said clinical trials are underway evaluating the potential of Humira in other autoimmune diseases.

Humira received European approval to treat patients with severe active ankylosing spondylitis on June 1.

Abbott is a global health care company located in Abbott Park, Ill.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.